NEWS

ConfometRx has solved the structure of GPR75 with a second proprietary ligand, featuring a distinct scaffold, at the resolution of 3.3Å.

ConfometRx has solved the structure of GPR75 with a proprietary ligand at the resolution of 3.1Å.

Awarded a 1-year SBIR phase 1 grant for discovery of GPR171 small molecule ligands for the treatment of chronic pain.

Awarded a 1-year SBIR phase 1 grant for discovery of GPR75 small molecule ligands for the treatment of obesity.

ConfometRx entered an agreement with Eli Lilly and Company and HitGen Inc. to begin work on a GPCR target.

Published the crystal structure of the D1 dopamine receptor in complex with the G protein Gs. This structure was obtained in Oct. 2015 as part of a collaboration with UCB.

Reported two high-resolution structures of the Glp1 receptor: one bound to a non-peptide agonist (LY3502970), and another bound to Glp1 peptide and a positive allosteric modulator (LSN3160440).

Awarded a 3-year SBIR phase 2 grant for structure-based drug discovery of dopamine D2 receptor selective ligands.

A high resolution structure of a target GPCR-G protein complex bound to a candidate compound was solved by cryo-EM. On December 2018, an additional GPCR target was added to this collaboration. Several high-resolution structures were delivered by Oct 2019.

Entered a Research Collaboration Agreement with Eli Lilly and Company to obtain GPCR structures with proprietary compounds.

Awarded a 5-year SBIR Fast-Track phase 1 & 2 grant for structure based drug discovery of dopamine D1 receptor selective small molecule ligands.

ConfometRx unlocks novel GPCR-G protein structure within UCB research collaboration. We are pleased to announce that it has succeeded in elucidating the crystallographic structure of a novel GPCR-G protein complex composed of a Family A GPCR coupled to its G protein, only the second reported GPCR-G protein complex.

Read More

Awarded a 1-year SBIR phase 1 grant for structure-based drug discovery of dopamine D2 receptor selective ligands.

Awarded a 3-year SBIR phase 1 & 2 grant for Developing Methods in Crystallizing and Drug Discovery for a Family B GPCR.

The structure of A2A Adenosine receptor bound to a novel antagonist was solved in collaboration with UCB Pharma.

ConfometRx Awarded Patent on GPCRs that Contain a Stabilizing IC2 Fusion Protein

Read More

ConfometRx and UCB Announce New R&D Partnership. Under this two-year multi-target agreement UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor (GPCR) modulation towards the design of differentiated drugs.

Read More

Brian Kobilka, co-founder, was awarded the Nobel Prize in Chemistry. His co-recipient is Robert Lefkowitz of Duke University.

Read More

Awarded a 3-year SBIR phase 2 grant for Developing Methods in Crystallizing a Family C GPCR.

The structure of M1 muscarinic receptor bound to an antagonist was solved.

Confometrx signed a multi-year collaborative agreement with Novo Nordisk A/S of Denmark to obtain crystal structures of a GPCR. Combining the extensive expertise of both companies, the goal is to discover newer and better therapeutic agents.

Awarded a 2-year SBIR phase 1 grant for Developing Methods in Crystallizing a Family C GPCR.

Awarded phase 1 SBIR grant for Developing Methods for Crystallizing Family B GPCRs.

Established a multi-year collaboration with Bristol-Myers Squibb Company to obtain crystal structures of G-protein coupled receptors to enable discovery of novel medicines for unmet medical needs.

Signed a collaborative, multi-year agreement with Lundbeck A/S of Denmark whereby ConfometRx, Inc will obtain crystal structures of two G-protein coupled receptors for Lundbeck A/S. The agreement is based on upfront and milestone payments.

Work on the second target from Medarex was initiated.

Awarded Phase I SBIR Grant to develop a fluorescent screening assay based on ConfoTeG technology.

ConfometRx has entered into a partnership with Medarex, Inc. to generate novel immunogens. We are providing Medarex with high-quality protein preparations produced using our proprietary technology for membrane-associated protein expression and purification.